3,6-Di-tert-butylcarbazole | CAS:37500-95-1

We serve 3,6-Di-tert-butylcarbazole CAS:37500-95-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3,6-Di-tert-butylcarbazole

Chemical Name:3,6-Di-tert-butylcarbazole
CAS.NO:37500-95-1
Synonyms:3,6-Di-tert-butyl-9H-carbazole
3,6-BIS(TERT-BUTYL)CARBAZOLE
3,6-ditert-butyl-9H-carbazole
Molecular Formula:C20H25N
Molecular Weight:279.41900
 
Physical and Chemical Properties:
Melting point:232ºC
 
Specification:
Appearance:White crystalline powder
Assay:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 3,6-Di-tert-butylcarbazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,6-ditert-butyl-9H-carbazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,6-Di-tert-butyl-9H-carbazole Use and application,3,6-BIS(TERT-BUTYL)CARBAZOLE technical grade,usp/ep/jp grade.


Related News: The target screening performed by Retrogenix will focus on hundreds of novel, prioritized antibodies in Resonant’s collection.5-(4-bromophenyl)pyrimidine-4,6-diol manufacturer The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds.3-Bromo-2-chloropyridine supplier The API is not made by only one reaction from the raw materials but rather it becomes an API via several chemical compounds.ethylpyrazine vendor After several years of R & D and improvement, the production process of commonly used generic drug bulk drugs is relatively mature, and the products of similar companies have high similarities. Therefore, the competitive advantage of bulk drug companies is mainly reflected in cost control. Companies with cost advantages can usually pass Competition to expand production capacity and further gain scale advantages, while having stable, high-quality upstream supply.The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally.